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Abstract
Lipoteichoic acids (LTA) are amphiphilic polymers that are important constituents of the cell wall of many Gram-positive
bacteria. The chemical structures of LTA vary among organisms, albeit in the majority of Gram-positive bacteria the LTAs
feature a common poly-1,3-(glycerolphosphate) backbone. Previously, the specificity of opsonic antibodies for this
backbone present in some Gram-positive bacteria has been demonstrated, suggesting that this minimal structure may be
sufficient for vaccine development. In the present work, we studied a well-defined synthetic LTA-fragment, which is able to
inhibit opsonic killing of polyclonal rabbit sera raised against native LTA from Enterococcus faecalis 12030. This promising
compound was conjugated with BSA and used to raise rabbit polyclonal antibodies. Subsequently, the opsonic activity of
this serum was tested in an opsonophagocytic assay and specificity was confirmed by an opsonophagocytic inhibition
assay. The conjugated LTA-fragment was able to induce specific opsonic antibodies that mediate killing of the clinical
strains E. faecalis 12030, Enterococcus faecium E1162, and community-acquired Staphylococcus aureus strain MW2 (USA400).
Prophylactic immunization with the teichoic acid conjugate and with the rabbit serum raised against this compound was
evaluated in active and passive immunization studies in mice, and in an enterococcal endocarditis rat model. In all animal
models, a statistically significant reduction of colony counts was observed indicating that the novel synthetic LTA-fragment
conjugate is a promising vaccine candidate for active or passive immunotherapy against E. faecalis and other Gram-positive
bacteria.
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Introduction
The incidence of infections caused by multidrug resistant
enterococci has become a worldwide problem over the last
decades, particularly in immunocompromised patients [1].
Acquired resistance to b-lactams and vancomycin has spread
almost through all patient populations, not only making nosoco-
mial infections caused by this genus extremely difficult to treat, but
also highlighting the necessity to develop alternative treatments
[2]. Effective immunotherapies are usually directed against
virulence factors like capsular polysaccharides that are present
on the outside of the bacterial membrane and which often play a
role to evade host responses [3]. Our group has previously
identified an enterococcal surface antigen, lipoteichoic acid (LTA),
present in nonencapsulated E. faecalis strains, that is able to
induce opsonic antibodies and protect against E. faecalis and E.
faecium bacteremia [4].
Lipoteichoic acids are amphiphilic glycoconjugate polymers and
are important constituents of the cell wall of many Gram-positive
bacteria such as staphylococci, streptococci, bacilli, clostridia,
corynebacteria and listeria [3,5]. They play crucial roles in cell
division, membrane elasticity, porosity and anchoring of surface
proteins [3,6]. The chemical structure of LTAs varies among
organisms, but in the majority of Gram-positive bacteria LTA has
a relatively conserved poly-1,3-(glycerolphosphate) backbone
structure with limited variability, which may be due to its
biosynthetic pathway [7,8]. This backbone represents the shared
epitope amongst different bacterial strains and variation of the
LTA structures between organisms originates from the type and
number of carbohydrate appendages and length of the poly-
glycerol phosphate chain [3]. The glycolipid anchor of LTA has
been reported to be an integral part of the immunostimulatory
activity of LTA, although it has also been argued that lipopeptides
and lipoproteins that contaminate LTA when isolated from
biological sources, are responsible for this activity. The poly-
glycerol-phosphate backbone has no innate immunostimulatory
activity itself and small teichoic acid fragments are poor
immunogens [9–11]. Polysaccharide antigens that are intrinsically
poorly immunogenic [12] are often conjugated to a carrier protein
to elicit optimal anti-polysaccharide responses, and to induce
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humoral immune responses with the characteristics of a T-cell
dependent antigen [12,13]. Synthetic oligosaccharide-protein
conjugate vaccines have emerged recently as an interesting
strategy in vaccinology, since they offer two major advantages: a
well-defined chemical structure (chain length, nature of the
epitope, well-established carbohydrate/protein ratio, single type
of linkage between the antigen and the carrier) and lack of
impurities present in polysaccharides obtained from bacterial
cultures [14,15]. This would apply also for a teichoic acid-based
vaccine. The accessibility of the highly conserved LTA polymer on
the cell surface, its relatively uniform basic structure and its non-
inflammatory nature would be advantages of a synthetic LTA
vaccine that targets a wide variety of LTAs in different Gram-
positive pathogens. Very recently, a tetanus toxoid conjugate of a
10-mer polyglycerolphosphate (PGP) was evaluated for its
potential use as a conjugate vaccine directed against S. aureus
[11]. Chen and coworkers evaluated the use of this PGP as a
prophylactic conjugated vaccine in a mouse model and were able
to demonstrate that serum raised against the conjugate elicits
specific IgG capable of enhancing in vitro opsonophagocytic
killing of S. aureus strains and clearance of staphylococcal
bacteremia in vivo [11]. Although Chen et al. did not evaluate
the potential use of this PGP-based conjugate vaccine against
other Gram-positive pathogens, they suggest cross-protection
against organisms expressing this highly conserved backbone [11].
We have previously shown that opsonic antibodies directed
against LTA from E. faecalis are cross-reactive against LTA
present in Staphylococcus epidermidis, Staphylococcus aureus and
group B streptococci, and that they mainly bind to the poly-1,3-
(glycerolphosphate) backbone, suggesting that this minimal struc-
ture may be sufficient for vaccine development against some
Gram-positive bacteria [8]. We also have previously demonstrated
that short synthetic oligoglycerol phosphates are able to absorb up
to 91% of the opsonophagocytic killing of serum raised against
LTA from E. faecalis 12030 against the homologous strain and
also against S. aureus strains, indicating that these synthetic
antigens could be used as templates for vaccine development
[8,16]. In the present study, we evaluated the antigenicity of well-
defined synthetic teichoic acid fragments and the development of a
synthetic TA-protein conjugate as a vaccine candidate. We show
that the semi-synthetic model vaccine modality is capable of
eliciting opsonic and protective antibodies that promote in vitro
opsonophagocytic killing, clearance of bacteria after active and
passive immunization and effectively protect against enterococcal
bacteremia in a rat endocarditis model.
Materials and Methods
Synthesis of Teichoic Acid Fragments
The short teichoic acid fragments used in this study were
synthesized as described earlier using a combination of solution
phase, light fluorous supported and automated solid phase
techniques [8,17–19]. To scale up the synthesis of the hexaglycer-
olphosphate with a single glycosyl appendage (WH7, see
Figure 1A), a light fluorous supported synthesis was applied [19].
Kojibiosyl [a-Glc-1R2-a-Glc] functionalized hexaglycerol phos-
phate (WH5, Figure 1B) was assembled using a solution phase
synthesis approach [17].
Synthesis of the Model Teichoic Acid Vaccine
Maleimides derivatives of WH7 and WH5 were obtained by
treatment of the glycosylated glycerol phosphate hexamers [16]
with N-succinimidyl-3-maleimido propionate ester (See Support-
ing Information S1 for full experimental details and characteriza-
tion of the new compounds). Bovine serum albumin BSA was
thiolated as described by Verez-Bencomo and co-workers [21] by
treatment with thiopropionic acid hydroxysuccinimide ester
homodisulfide and subsequent reduction of the disulfides. Quan-
tification of the thiols using Ellman’s reagent indicated that 643
thiol groups per BSA molecule were present. The maleimides of
WH7 and WH5 were then conjugated with thiolated-BSA through
a Michael type addition [20,21] to give conjugates WH7-BSA and
WH5-BSA. The teichoic acid conjugates were purified by dialysis
and analyzed by SDS-PAGE, which revealed a broad band for the
conjugates around 95 KDa and 100 KDa for the WH7 and
WH5-conjugates, respectively (Figure 2). The conjugates were also
analyzed on protein and sugar content. Combined, these analyses
indicated that approximately 20 teichoic acid fragments per BSA
molecule were installed.
Purification of LTA
Lipoteichoic acid from E. faecalis 12030 was obtained by
butanol extraction as described elsewhere [6].
Bacterial Strains and Rabbit Immunizations
The bacterial strains used in this study were the clinical strains
E. faecalis 12030 [22], E. faecium 1162 [23] and community-
acquired S. aureus MW2 (USA400) [24]. A New Zealand white
rabbit was immunized with purified LTA from E. faecalis 12030
as described elsewhere (anti-LTA) [4]. Three more rabbits were
immunized with synthetic LTA WH5 conjugated with BSA
(antiWH5-BSA), synthetic LTA WH7 conjugated with BSA
(antiWH7-BSA), and unmodified BSA (anti-BSA). Two subcuta-
neous injections of 10 mg of conjugate or protein were given 2
weeks apart together with Freund’s incomplete antigen; in the
fourth and eighth week, three injections of 5 mg were given
intravenously; and a final bleed was collected in the ninth week.
All sera samples were heat-inactivated at 56uC for 30 min to
inactivate complement components. For all experiments, sera from
the final bleed of the rabbit were used.
Measurement of antigen (LTA and WH7)-specific IgG
titers in rabbit immune sera
Total IgG concentration was determined in each pre-bleed, test
bleed (i.e. after 5th antigen injection) and terminal bleed sera with
the Easy-Titer Rabbit IgG Assay kit (Thermo Scientific) according
Figure 1. Structure of synthetic teichoic acid hexamers WH5 (A)
and WH7 (B).
doi:10.1371/journal.pone.0110953.g001
Synthetic Teichoic Acid Vaccine
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e110953
to the manufacturer’s instructions. Total IgG concentration in
each serum sample was adjusted to 9.3 mg IgG/mL and serum
specific IgG titers against WH7 or LTA were measured by ELISA.
Nunc-immuno Maxisorp MicroWell 96 well plates were coated
either with 0.2 mg of WH7 antigen (previously conjugated with
Tetanus Toxoid as described by Hoogerhout and co-workers
[25,26]) or 0.125 mg of LTA from S. aureus purchased from
Sigma (St. Louis, Mo.) in 0.2M carbonate-bicarbonate coating
buffer. Plates were incubated overnight at 4uC, washed three times
after incubation with PBS containing 0.05% Tween 20 and
blocked with 3% cold water fish skin gelatin (Sigma, St. Lois, Mo.)
in PBS at 37uC for 2 hours. Rabbit sera were plated in twofold
serial dilutions and incubated 1 hour at 37uC, starting with a
dilution of 1:12.5 for each serum tested. Alkaline-phosphatase-
conjugated anti-rabbit IgG produced in goat (Sigma) diluted
1:1.000 was used as secondary antibody and p-nitrophenyl
phosphate (Sigma) was used as substrate (1 mg/mL in 0.1M
glycine, 1 mM MgCl2, 1 mM ZnCl2, pH 10.4). After 60 min of
incubation at room temperature, the absorbance was measured at
405 nm on a Tecan Infinite 200 PRO (Tecan Group Ltd.). Each
experiment was performed twice at different time-points, and wells
were measured in quadruplicate, with a coefficient of variation for
each measured sample less than 12%. Serum Ig titers were
calculated as follows: For each serum sample, a plot of OD value
against the reciprocal of the dilution (Log(1/dilution)) was used to
calculate the intercept with the specified cutoff value of each test,
and this value was taken as the ELISA end point titer. The value
extrapolated from the standard curve was then multiplied by the
inverse of that dilution to generate the final inverse titer [27].
Opsonophagocytic Assay
An in vitro opsonophagocytic assay (OPA) was performed as
described elsewhere [28] using baby rabbit serum as complement
source and rabbit sera raised against either purified LTA or the
conjugated synthetic LTA antigens. White blood cells (WBCs)
were freshly prepared from human blood collected from healthy
adult volunteers. Bacterial strains were grown to an
OD650 nm = 0.400 in tryptic soy broth (TSB). For the assay, the
following components were mixed: 100 ml of PMNs; 100 ml of
serum dilutions (as indicated), 100 ml of absorbed baby rabbit
complement at a dilution of 1:15 and 100 ml of the bacterial
suspension adjusted to the desired colony counts (i.e. 1:1 relation
PMNs/bacteria). The mixture was incubated on a rotor rack at
37uC for 90 min, and samples were plated in duplicate at time 0
and after 90 min. Percent killing was calculated by comparing the
colony forming units (CFUs) surviving in the tubes with bacteria,
WBCs, complement and antibody, to the CFUs surviving in the
tubes with all these components but lacking WBCs. Each
experiment was performed at least twice, under the same
conditions and with different blood donors, and measured in
quadruplicate samples. Variation in the percentage of killing
between the two independent experiments was less than 15%,
showing the same trend and indicating the reliability of the
procedure and the reproducibility of the experiment.
Opsonophagocytic Inhibition Assay (OPIA)
Synthetic TA mimetics and purified LTA from E. faecalis
12030 were used to evaluate its function as inhibitors of the
opsonic killing generated by anti-LTA serum at different
concentrations (from 0.08 to 100 mg/mL), by incubating them
for 60 minutes at 4uC with an equal volume of a 1:200 dilution of
anti-LTA serum or the sera raised against WH7. After this
incubation step, the opsonophagocytic assay was performed as
described above using the mix inhibitor/anti-LTA or inhibitor/
anti-WH7-BSA serum instead of the serum dilutions. Inhibition
assays were performed at serum dilutions yielding 70 to 80% of
opsonic killing of the inoculum without the addition of the
inhibitor. The inhibition of killing was calculated as the percentage
of CFUs surviving opsonophagocytic killing when the inhibitor
was used compared to those surviving when no inhibitor was
present. Each experiment was performed at least twice, under the
same conditions and with different blood donors, and measured in
quadruplicate samples. Variation in the percentage of killing
between the two independent experiments was less than 15%,
Figure 2. Synthesis of WH5-BSA and WH7-BSA conjugates.
doi:10.1371/journal.pone.0110953.g002
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showing the same trend and indicating the reliability of the
procedure and the reproducibility of the experiment.
Whole cell ELISA
Bacterial strains E. faecalis 12030, E. faecium E1162 and S.
aureus MW2, were grown in tryptic soy agar overnight and
resuspended in PBS to an OD650 of 0.4 (,56108 CFU/mL).
From each bacterial suspension, 100 mL was added to wells of
Nunc-immuno Maxisorp MicroWell 96 well plates and incubated
overnight at 4uC. The wells were washed three times with PBS
containing 0.05% Tween 20. After washing, the wells were
blocked with PBS containing 3% cold water fish skin gelatin
(Sigma, St. Louis, Mo.) for 2 h at 37uC. Antibodies normal rabbit
serum (NRS), anti-LTA, anti WH5-BSA and anti WH7-BSA were
tested at 1:100 dilution, with final concentration of 93 mg IgG’s/
mL. Alkaline-phosphatase conjugated anti-rabbit IgG produced in
goat (Sigma) diluted 1:1,000 was used as secondary antibody and
p-nitrophenyl phosphate (Sigma) was used as substrate (1 mg/mL
in 0.1M glycine, 1 mM MgCl2, 1 mM ZnCl2, pH 10.4). After
60 min of incubation at room temperature, the absorbance was
measured at 405 nm on a Tecan Infinite 200 PRO (Tecan Group
Ltd.). Each experiment was performed twice, measured in
quadruplicate samples, with a coefficient of variation for each
measured sample less than 15%. Both antibodies were diluted in
PBS with 1% cold water fish skin gelatin.
Mouse Sepsis Model – Active Immunization
Six to eight week-old female BALB/c mice (Charles River
Laboratories Germany GmbH) were vaccinated with WH7-BSA
conjugate or unmodified BSA antigens. Mice were injected
subcutaneously with 10 mg of antigen emulsified in 100 ml
complete Freund’s adjuvant. Eight days post vaccination mice
were boosted subcutaneously with 10 mg of antigen emulsified in
100 ml incomplete Freund’s adjuvant. On days 14, 16, 18, 32 and
35 mice were boosted intraperitoneally with 5 mg of antigen
suspended in saline. Challenge of the vaccinated mice was
performed intravenously seven days after final boost with
36107 CFUs of E. faecalis 12030. Mice were sacrificed 24 hours
after challenge and colony counts in the liver were determined.
Mouse Sepsis Model – Passive Immunization
The model was performed as previously described [4]. In brief,
six to eight week-old female BALB/c mice (Charles River
Laboratories Germany GmbH) were immunized i.p. with
100 mL of anti WH7-BSA serum or normal rabbit serum (NRS).
After 24 hours, mice were infected i.v. with 9.46106 CFUs of E.
faecalis 12030 via the tail vein. Mice were sacrificed 24 hours after
challenge and colony counts in liver were determined.
Rat Endocarditis Model
A rat endocarditis model was performed as described previously
[29]. In brief, female Wistar rats (Charles River Laboratories
Germany GmbH), were anesthetized with 5.75% ketamine and
0.2% xylazine. Nonbacterial thrombotic endocarditis was caused
by insertion of a plastic catheter (polyethylene tubing; Intramedic
PE 10) via the right carotid artery. The catheter was advanced
through the aortic valve into the left ventricle, secured properly
and left in place. Rats were monitored closely after the catheter
implantation. Ten rats were randomly separated in two groups,
one received intravenously 500 mL of normal rabbit sera (NRS,
Cedarlane, Burlington, Canada) during catheter implantation, and
the second group received 500 mL of the anti WH7-BSA serum.
An injection of 500 mL of NRS and anti WH7-BSA was made i.p.
after 24 hours of catheter implantation and 4 hours after bacterial
challenge. An inoculum of 1.186105 C.F.U.s of E. faecalis 12030
was injected via the tail vein in each rat 48 hours after catheter
implantation. On postoperative day 6, rats were sacrificed and the
correct placement of the catheter was verified. Valve vegetations
were removed aseptically, weighed and homogenized in 500 mL
TSB. Quantitative assessment was performed by weighing the
vegetations as well as culturing serial dilutions on agar plates
incubated over night at 37uC. Only animals with correct
placement of the catheter were included in the study.
Statistics
The software program GraphPad PRISM version 5.00 was used
for statistical analysis. The percentage of opsonophagocytic killing
and absorbance in whole-cell ELISA was expressed as the
geometrical mean 6 the standard errors of the means and
statistical significance was determined by one way ANOVA with
Dunnett’s post-test for multiple comparisons of groups. For animal
models statistical significance was determined by nonparametric t-
test with Mann-Whitney post-test and P values #0.05 were
considered statistically significant.
Ethics Statement
All animal experiments were performed in compliance with the
German animal protection law (TierSchG). The mice and rats
were housed and handled in accordance with good animal
practice as defined by FELASA and the national animal welfare
body GV-SOLAS. The animal welfare committees of the
University of Freiburg (Regierungspra¨sidium Freiburg Az 35/
9185.81/G-07/15, Az 35/9185.81/G07-72) approved all animal
experiments.
Results
Synthetic antigen selection and synthesis of the teichoic
acid carrier protein conjugates
The library of teichoic acid fragments we have synthesized
contains fragments varying in length (ranging from 6 to 30 glycerol
phosphate monomers), glycosylation pattern (a-glucosyl, a-koji-
biosyl, a-glucosamine and a-N-acetyl glucosamine) and terminal
functionality (either a phosphate or primary alcohol) [8,16,17].
From this library we have selected WH7 as an optimal synthetic
antigen because of its ability to inhibit the opsonic killing of
antibodies raised against LTA from E. faecalis 12030 by more
than 80% (See Figure 3) [16]. Furthermore, the synthesis of WH7
can be readily scaled to provide enough material allowing the
generation of sufficient amounts of the conjugate [19]. Surprisingly
we have found that the analogous WH5, featuring an a-kojibiosyl
substituent that is found in native E. faecalis LTA is devoid of such
activity (Figure 3). Therefore, WH5 was chosen as a negative
control and both synthetic TA fragments were conjugated to BSA.
To this end, the approach used by Verez-Bencomo et al. for the
development of the Quimihib-vaccine [20] was employed, because
of the structural similarities between the Hib ribitol-based
polysaccharide and the synthetic TA fragments at hand. We
selected BSA as a carrier protein because of its stability, ease of
handling, favorable molecular weight, non-glycosylated nature
and modification possibilities. The TA fragments, functionalized
with a primary amine spacer, were equipped with a reactive
maleimide group and conjugated to thiolated BSA as depicted in
Figure 2. The obtained conjugates were characterized by SDS-
PAGE and analyzed for carbohydrate and protein content,
revealing a carbohydrate-protein ratio of ,1.5: 1, indicating that
Synthetic Teichoic Acid Vaccine
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approximately 20 copies of antigen were present per carrier
molecule.
LTA and teichoic acid fragment-specific IgGs are induced
after rabbit immunizations
According to figure 4, LTA-specific IgG antibodies were
generated during each immunization procedure using either
native LTA from E. faecalis 12030 (Figure 4A) or WH7-BSA
conjugate (Figure 4B). Antibodies raised against the synthetic
hexamer WH7 are able to bind and recognize native LTA, but to
a lesser extent than antibodies raised against the whole LTA
molecule, while only a very low titer is observed for the terminal
bleed of anti WH5-BSA serum. A different behavior is observed
for WH7 titers of anti-LTA and anti WH7-BSA sera, where higher
titers were obtained for anti WH7-BSA serum in comparison to
anti-LTA serum.
Teichoic acid conjugates WH5-BSA and WH7-BSA
induced antibodies with opsonic activity
To confirm that opsonic antibodies were induced by the
immunization with the conjugate WH7-BSA but not by immu-
nization with BSA or the WH5-BSA conjugate, the opsonopha-
gocytic activity of the sera was tested by OPA using S. aureus
MW2 as target strain since this strain was shown to be sensitive to
anti-LTA antibodies raised against LTA from E. faecalis 12030.
At a serum dilution of 1:10 and 1:50, the serum raised against BSA
was not able to mediate opsonic killing against S. aureus MW2. A
similar behavior was observed for the WH5-BSA serum, with very
low opsonophagocytic killing (,10%). On the other hand, the
Figure 3. Evaluation of anti-LTA antibodies specificity for synthetic LTA hexamers and native LTA. Antibodies raised against LTA from E.
faecalis 12030 were evaluated for their ability to bind specifically the different synthetic TA hexamers WH5 and WH7, and native LTA purified from E.
faecalis 12030 (nLTA). Anti-LTA sera was used at final dilution of 1:200 and the strain tested was E. faecalis 12030. Inhibitors WH5, WH7 and nLTA at
concentrations of 100, 20, 4 and 0.8 mg/mL were preincubated with anti-LTA antibodies for 1 hour at 4uC prior OPA. Opsonic killing of the target
strain with non-absorbed antibodies was used to assess the reduction of opsonic killing produced by each inhibitor. All inhibitors tested showed
statistical significance in comparison to control anti-LTA serum (P value ,0.001). The corresponding dilutions of inhibitor used in the OPA are
indicated in the x-axis and the % killing in the y-axis. Bars represent the mean of data and the error bars represent the standard error of the mean.
doi:10.1371/journal.pone.0110953.g003
Figure 4. LTA and WH7 -specific IgG antibody titer curves. (A) LTA from S.aureus specific IgG titers of sera raised against native LTA (Anti-LTA),
synthetic WH5-BSA conjugate (Anti WH5-BSA) and synthetic WH7-BSA conjugate (Anti WH7-BSA). (B) WH7 specific IgG titers of sera raised against
native LTA (Anti-LTA) and synthetic WH7-BSA conjugate (Anti WH7-BSA).
doi:10.1371/journal.pone.0110953.g004
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WH7-BSA serum elicited high opsonophagocytic activity (.60%)
for both serum dilutions (Figure 5).
Opsonic antibodies to WH7-BSA conjugate are specific
against the teichoic acid conjugate
To confirm the specificity of the opsonic antibodies to WH7-
BSA, an opsonophagocytic inhibition assay (OPIA) was performed
by preincubation of anti WH7-BSA serum with a range of
dilutions of the synthetic WH7-BSA conjugate. The teichoic acid-
conjugate was a potent inhibitor of the opsonophagocytic killing
activity of the serum, not only against E. faecalis 12030, but also
against E. faecium E1162 (an E. faecium strain sensitive to anti-
LTA antibodies). In all cases, the inhibition of anti WH7-BSA
antibodies is directly proportional to the amount of inhibitor
added (Figure 6).
Opsonic antibodies to WH7-BSA conjugate are cross-
reactive
To explore the specificity of the antibodies directed to the
WH7-BSA conjugate for the LTA expressed by Gram-positive
bacteria, the opsonic activity towards the strains E. faecium
E1162, S. aureus MW2 and E. faecalis 12030 was evaluated.
Different concentrations of the serum were tested to titer out the
opsonic killing activity of the antibodies. Although it was observed
that anti WH7-BSA serum can mediate opsonic killing of all
strains tested (Figure 7), the enterococcal strains are effectively
killed at higher dilutions than S. aureus MW2.
Antibodies directed against LTA and WH7-BSA conjugate
bind bacterial cells
Immunoreactivity of tested sera against whole bacterial cells was
analyzed by whole-cell ELISA (Figure 8). Immune sera anti-LTA,
anti WH5-BSA and anti WH7-BSA showed statistically significant
binding to cells of E. faecalis 12030, E. faecium E1162 and S.
aureus MW2, in comparison with control serum (NRS) (* P,0.05,
*** P,0.001). Anti-LTA serum showed stronger signal binding to
E. faecalis 12030 cells, while anti WH5-BSA serum elicited poor
binding to E. faecalis and E. faecium cells. Serum raised against
WH7-BSA-conjugate bound well to all bacterial strains tested.
Vaccination with WH7-BSA conjugate and immunization
with anti WH7-BSA serum promotes clearance of bacteria
in mice
To demonstrate protection by the teichoic acid conjugate, active
immunization with the purified teichoic acid conjugate was
performed in mice. After 2 injections of 10 mg/mouse and 5
injections of 5 mg/mouse, animals showed statistically significantly
reduced numbers of E. faecalis 12030 in livers 24 hours after
inoculation (Figure 9A). In another set of experiments, prophy-
lactic treatment with antibodies raised against the WH7-BSA
conjugate significantly reduces bacterial counts in mice. Applica-
tion of 100 ml anti WH7-BSA serum per mouse 24 hours before
bacterial challenge resulted in less bacteria (reduction by factor 5)
at 24 hours after inoculation (Figure 9B).
Opsonic antibodies to WH7-BSA conjugate are protective
in a rat enterococcal endocarditis model
To explore if the opsonophagocytic activity of anti WH7-BSA
antibodies correlated with an in vivo infection model, a rat
endocarditis model was performed. Passive immunization with 3
doses of 500 mL of anti WH7-BSA antibodies resulted in dramatic
reductions of CFUs and also a significant reduction in valve
vegetations (P,0.05) compared to controls (Figure 10); anti WH7-
BSA serum mediated complete clearance of E. faecalis 12030 in
more than 50% of the rats, while all control rats showed
endocarditis.
Discussion
The use of polysaccharide-conjugate vaccines has rapidly
emerged as a suitable strategy to combat different pathogenic
bacteria. It includes the development of effective vaccines against
Haemophilus influenzae type b, Streptococcus pneumoniae, Neis-
seria meningitidis, Salmonella typhi and S. aureus [13–15,30].
Many of these approaches have focused on targeting different
Figure 5. Opsonophagocytic assay. This experiment was used to
test the ability of antibodies raised against conjugates with WH5 and
WH7, and BSA to mediate killing in the strain S. aureus MW2. Anti WH7-
BSA sera mediate opsonophagocytic killing of S. aureus MW2 in vitro,
while the sera anti-BSA and anti-WH5-BSA do not. Comparison of killing
percentages of same dilutions (i.e. 1:10 or 1:50) with control anti BSA
serum, only showed statistical significance for anti WH7-BSA (*** P value
,0.001). The different sera and the corresponding dilutions used in the
OPA are indicated on the x-axis and the % killing on the y-axis. Bars
represent the mean of data and the error bars represent the standard
error of the mean.
doi:10.1371/journal.pone.0110953.g005
Figure 6. Specificity of anti WH7-BSA serum to WH7-BSA
conjugate. Anti WH7-BSA serum was used at final dilution of 1:5,000
and the strains tested were E. faecalis 12030 and E. faecium E1162.
Inhibitor WH7-BSA conjugate at different concentrations 100, 20, 4 and
0.8 mg/mL was preincubated with anti-LTA antibodies for 1 hour at 4uC
prior OPA. Opsonic killing of the target strain with non-absorbed
antibodies was used to assess the reduction of opsonic killing produced
by each inhibitor, asterisks denote statistical significance (** P,0.01, ***
P value ,0.001). The corresponding dilutions of inhibitor used in the
OPA are indicated on the x-axis and the % killing on the y-axis. Bars
represent the mean of data and the error bars represent the standard
error of the mean.
doi:10.1371/journal.pone.0110953.g006
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serotypes by the identification of conserved surface carbohydrate
structures. LTAs from different common pathogens have been
evaluated as possible vaccine candidates against bacterial infec-
tions. Intranasal co-administration of LTA from Streptococcus
pyogenes with cholera toxin subunit B had induced good
pharyngeal IgA and systemic IgGs, suggesting its use as an
effective approach in prevention of tonsillitis [31]. Rabbit sera
raised against conjugated LTA from Clostridium difficile have
shown immunoreactivity with cells and spores from other C.
difficile strains; however, no protection studies have been
conducted [32]. In a different approach, Goldenberg and
coworkers have demonstrated the ability of human antibodies
directed against the phosphorylcholine to protect mice from a
lethal dose of S. pneumonia. This antigenic component of LTA
from S. pneunomiae and of the lipopolysaccharide from H.
influenzae has been proposed as a vaccine candidate against
pathogenic bacteria residing the upper respiratory tract [33].
Various synthetic approaches have been reported towards the
assembly of well-defined teichoic acid structures of different
pathogens, including Clostridium difficile [34,35], E. faecalis [7,8]
and S. aureus [11,19]. Martin et al. have described the synthesis of
oligomers of the LTA antigen in C. difficile and used these
fragments to define epitopes for vaccine development based on
interactions of anti-LTA antibodies with bacteria in the blood of
patients. However, no protective efficacy of antibodies directed
against the synthetic oligomers has been reported so far [35]. To
date, only a chimeric monoclonal antibody developed against LTA
from S. aureus has been used in clinical trials. Pagibaximab has
shown efficacy promoting staphylococcal phagocytosis and
survival of animals challenged with coagulase-negative straphylo-
cocci [36,37]. This vaccine appeared safe and well tolerated in
healthy adult volunteers and very-low-weight neonates; however,
no clear protection has been observed against staphylococcal sepsis
in this setting [36–39].
Despite the already demonstrated importance of specific
antibodies directed against LTA in the treatment of infections
caused by many Gram-positive pathogens, the protective efficacy
of human pre-existing antibodies, either against LTA structures or
phosphorylcholine, is still questionable [33,40]. Hufnagel and
coworkers attribute this fact to the low specificity of pre-existing
Figure 7. Opsonophagocytic killing activity of anti WH7-BSA antibodies against Gram-positive bacterial strains. The antibodies raised
against WH7-BSA conjugate were used at different dilutions 1:10, 1:100, 1:1000, 1:10.000, 1:20.000, 1:160.000 and 1:200.000, as shown in the x-axis, to
assess % killing activity of the target strains E. faecalis 12030, E. faecium E1162 and S. aureus MW2. Bars represent the mean of data and the error bars
represent the standard error of the mean.
doi:10.1371/journal.pone.0110953.g007
Figure 8. Whole-cell ELISA. Whole cell ELISA of E. faecalis 12030, E. faecium E1162 and S.aureus MW2 using normal rabbit serum (NRS- white bar),
anti-LTA serum (grey bar), anti WH5-BSA serum (grey diagonally-striped bar) and anti WH7-BSA serum (black bar). Statistical significance performed
by one way ANOVA with Dunnett’s post-test for multiple comparison of groups, is denoted in asterisks (* P,0.05, ** P,0.01, *** P,0.001) and was
calculated comparing the means of absorbance for each anti sera sample with serum control (NRS).
doi:10.1371/journal.pone.0110953.g008
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human LTA antibodies and their non-opsonic nature [40]. Others
have explain this biological behavior on the basis of individual
variation in IgG subclasses, differences in affinity or avidity, or low
specificity of naturally acquired antibodies [33,41,42].
We have shown previously that the cross-reactive epitope of
anti-LTA antibodies is the poly-1,3-(glycerolphosphate) backbone
of LTA in staphylococcal, streptococcal and enterococcal strains;
likewise, their ability to opsonize and protect against E. faecalis, E.
faecium, S. aureus and S. epidermidis bacteremia has been
demonstrated [4,6,8,43]. In the current study, two synthetic TA
hexamers with different glycosyl substituents were chosen accord-
ing to their ability to absorb out opsonic anti-LTA antibodies, and
their immunogenicity was evaluated after conjugation with a
carrier protein. It was found that the kojibiosyl-functionalized TA-
conjugate proved ineffective in eliciting opsonic antibodies, which
seems to indicate that the kojibiosyl moiety present in the WH5
hexamer probably masks the polyglycerolphosphate backbone.
Indeed, we have previously found that the kojibiosyl hexaglycer-
olphosphate WH5 is unable to inhibit opsonophagocytic killing of
E. faecalis by serum raised against LTA [8]. On the other hand,
the ability of hexamer WH7 to inhibit, in a dose-dependent
fashion, the opsonic killing activity of anti-LTA antibodies to E.
faecalis 12030 was confirmed in agreement with previous findings
[16]. The conjugate WH7-BSA was able to induce high-titered
opsonic and specific antibodies, showing cross-reactivity with two
other pathogenic Gram-positive species. The lower opsonopha-
gocytic killing observed in the staphylococcal strain may be
explained by the ability of capsular polysaccharides present in the
cell wall of some Gram-positive strains to mask components in the
cell wall [8,44,45]. Additionally, the opsonic killing activity of the
anti WH7-BSA serum observed by OPA, correlates with the
ability of the TA conjugate antigen to induce antibodies that
promotes clearance of bacteria in the liver of mice, either by active
or passive immunization and to protect rats against enterococcal
endocarditis by passive immunization. The active immunization
schedule used here was chosen because pilot experiments
confirmed effective induction of high titers of opsonic antibodies.
However, since we did not measure titers against the antigens after
Figure 9. Mouse Sepsis Models. Active Immunization with WH7-BSA conjugate promotes clearance of E. faecalis 12030 in liver in comparison with
vaccination with unmodified BSA (A). Passive immunization with anti WH7-BSA serum facilitates clearance of E. faecalis in liver in comparison with
normal rabbit serum (NRS) (B). After 24 hours of challenging mice were killed, kidney and liver were removed to assess viable counts. Statistical
analysis was done by Students t-test, horizontal bars represent geometric means, and a P value ,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0110953.g009
Figure 10. Passive immunization with anti WH7-BSA serum protects rats against enterococcal endocarditis. Thirteen female Wistar rats
were catheterized, passively immunized 2 times with 500 mL of anti WH7-BSA sera and NRS, and challenged after 48 hours with 1.186105 CFUs of E.
faecalis 12030. After challenging, rats were boosted with either 500 mL of NRS or anti WH7-BSA sera. Three days after challenging, animals were
sacrificed and valve vegetations were weighed and quantified. Horizontal lines indicate the geometric means of weighed valve vegetations (A) and
CFUs per mg of vegetation of E. faecalis 12030 (B). Significant P values are indicated on the graphs.
doi:10.1371/journal.pone.0110953.g010
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all the different injections we cannot assess how many applications
of antigen would be necessary to achieve protective titers.
The high affinity against LTA observed in the serum raised
against native LTA from E. faecalis 12030 is probably caused by
the diversity of antibodies against different epitopes of the
molecule. Although antibodies directed against the WH7-BSA
conjugate show lower binding than anti-LTA serum, these
antibodies may have a higher affinity for the specific antigenic
determinant present in the WH7 structure that represents the
protective epitope, enabling the sera to mediate better in vitro
opsonophagocytosis and protect animals against bacteremia or
endocarditis. Antibodies directed against different epitopes (i.e.
alanine residues present in native LTA but absent in WH7) that
are raised through immunization with native LTA do not bind to
the synthetic molecule, explaining the relatively low binding of
serum raised against native LTA to WH7. The results from the
whole cell ELISA confirm these findings since antibodies directed
against WH7-BSA are able to bind bacterial cells of E. faecalis
12030, E. faecium E1162 and S. aureus MW2, showing that there
is a direct relationship between the antibodies bound to the
bacterial cell surface and the ability of antibodies to mediate in
vitro opsonophagocytic killing or provide protection against
bacteremia and endocarditis in animal studies.
In summary, the data presented here describe the potential use
of a synthetic polyphosphoglycerol conjugate as vaccine candidate
in enterococci. To this end we have used a potent glycerol
phosphate hexamer, WH7, selected from a focused library of
synthetic TA structures, and conjugated this to BSA, a model
carrier protein. We were able to demonstrate that the WH7-BSA
conjugate induces specific and opsonic antibodies that promote
clearance of E. faecalis in the liver of mice and protect against
enterococcal endocarditis, suggesting that this teichoic acid
conjugate is a promising vaccine candidate against enterococcal
infections. Its use as a prophylactic vaccine will require further
studies of cross-reactivity against other enterococcal strains and
other Gram-positive bacterial species as well as different infection
models.
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